NCT04066296PHASE2Recruiting

Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine

University of Colorado, Denver

Start Date

9/8/2019

Completion Date

1/1/2025

Summary

Evaluate the benefit of using liposomal bupivicaine in lumbar laminectomies in terms of length of stay, IV narcotic use, 30-day narcotic use, visual analog score (VAS) and 30-day readmissions

Detailed Description

Recent evidence suggests the use of liposomal bupivicaine (LB) in lumbar spine surgery shortens length of hospital stay and overall post-operative narcotic use. Studies have shown its utility in single level microdiscectomies and lumbar fusions, but there have been no publications regarding lumbar laminectomies and associated outcomes with LB. The investigators' hypothesis is that LB will significantly shorten inpatient stays as well as overall narcotic usage in single, double or multi-level lumbar laminectomies.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. Male or Female 2. Adult (≥18 yo) 3. Lumbar stenosis Exclusion Criteria: 1. Co-morbidities precluding surgery 2. ≤18 yo 3. Pregnant 4. Breastfeeding 5. Need for instrumented fusion 6. Prisoners 7. Intra-operative CSF leak (identified by gush of CSF) 8. Daily pre-operative opioid use of \> 25 morphine Eq/day 9. Previous lumbar surgery at indicated level

Interventions

DRUG

Liposomal bupivacaine

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Lumbar Spinal Stenosis

Locations

University of Colorado Anschutz Medical Campus

Aurora, Colorado 80045

United States